GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that new preclinical
research on tumor growth and metastases and the potential value of its
newest drug candidate, GMI-1359,
will be presented at the American
Association for Cancer Research (AACR) Annual Meeting 2015 in
Philadelphia. Two posters will summarize research data on GMI-1359, a
dual acting antagonist of both E-selectin and CXCR4, demonstrating its
anti-tumor activity both alone and in combination with chemotherapy in
preclinical models of pancreatic and prostate tumor growth. A third
poster reports on preclinical studies where GMI-1271, an E-selectin
specific antagonist, demonstrates complimentary yet differing roles of
E-selectin and CXCR4 in breast cancer metastasis to bone. The AACR
Annual Meeting 2015 takes place from April 18 to 22, 2015, at the
Pennsylvania Convention Center.
“Our initial data supports further evaluation of our E-selectin-CXCR4
antagonist and its potential role in addressing a variety of cancers,
including those giving rise to bone metastases,” said John
Magnani, Ph.D., GlycoMimetics Vice President and Chief Scientific Officer.
“We are pleased to have an opportunity to share our pre-clinical data
with the research community and plan to continue our studies of this
promising drug and a novel approach to addressing some of the most
difficult to treat cancers.”
The AACR posters from GlycoMimetics, including abstract title, session
times, and locations, include the following:
-
“A Small Molecule Glycomimetic Antagonist of E-Selectin and CXCR4
(GMI-1359) Prevents Pancreatic Tumor Metastasis and Improves
Chemotherapy” [Tumor Biology: Cytokines and Chemokines and the
Microenvironment – Poster Session PO.TB06.01, Sunday, April 19, 2015,
1:00-5:00 p.m. Eastern Time] Abstract 425
-
“Dual E-selectin and CXCR4 Inhibition Reduces Tumor Growth and
Increases the Sensitivity To Docetaxel in Experimental Bone Metastases
of Prostate Cancer” [Tumor Biology: Cytokines and Chemokines and the
Microenvironment – Poster Session PO.TB06.01, Sunday, April 19, 2015,
1:00-5:00 p.m. Eastern Time] Abstract 428
-
“Metastatic Breast Cancer Cell Communication Within a Pro-dormancy
Bone Marrow Niche” [Tumor Biology: Dynamic Regulation of the Tumor
Microenvironment – Poster Session PO.TB06.08, Tuesday, April 21, 2015,
times 8:00-12:00 p.m. Eastern Time] Abstract #3212
About GlycoMimetics, Inc.
GlycoMimetics is a clinical stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. Pfizer is the company's development partner for
rivipansel, a GlycoMimetics-discovered investigational therapy for pain
crisis associated with sickle cell disease, and is preparing to conduct
a Phase 3 clinical study. A GlycoMimetics wholly-owned candidate therapy
(GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is
also in clinical trials. Glycomimetics are molecules that mimic the
structure of carbohydrates involved in important biological processes.
Using its expertise in carbohydrate chemistry and knowledge of
carbohydrate biology, GlycoMimetics is developing a pipeline of
glycomimetic drug candidates that inhibit disease-related functions of
carbohydrates, such as the roles they play in inflammation, cancer and
infection. Learn more at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of GMI-1359 and of GMI-1271. Actual results may
differ materially from those in these forward-looking statements. For a
further description of the risks associated with these statements, as
well as other risks facing GlycoMimetics, please see the risk factors
described in the Company’s quarterly report on Form 10-K that was filed
with the U.S. Securities and Exchange Commission on March 16, 2015, and
other filings the Company makes with the SEC from time to time.
Forward-looking statements speak only as of the date of this release,
and GlycoMimetics undertakes no obligation to update or revise these
statements, except as may be required by law.
Copyright Business Wire 2015